8-K/A: Cannabist Sells Virginia Assets to Curaleaf for $110M

The Cannabist Company has agreed to sell its Virginia cannabis cultivation, production, and retail assets to a Curaleaf subsidiary for $110 million, as part of a strategic review.

Summary

• The Cannabist Company Holdings Inc. (the Company) has entered into an Equity Purchase Agreement to sell all ownership interests of its subsidiary, Green Leaf Medical of Virginia, LLC (gLeaf Virginia), to Curaleaf, Inc., a subsidiary of Curaleaf Holdings Inc.
• The total consideration for the transaction is $110 million, subject to adjustment.
• The consideration consists of $80 million in cash payable at closing, $20 million in cash as deferred consideration (the Delayed Payment), and a $10 million promissory note.
• The assets being sold include 5 active retail locations, 1 additional retail location under development, and approximately 82,000 square feet of cultivation and production capacity in the Richmond, Virginia region.
• The transaction is part of a strategic review initiated by the Company's Board of Directors through a special committee of independent directors.
• The Company expects to use a portion of the net proceeds from the transaction to redeem its Senior Secured Notes.
• The transaction is subject to regulatory approvals and consent from holders of the Company's Senior Secured Notes.

Sentiment

Score: 6

Explanation: The sale of Virginia assets for $110 million provides a significant capital infusion and is part of a strategic review to address industry challenges and federal regulatory uncertainty. However, the deferred payment structure, potential downward adjustments to the promissory note, and the inherent risks associated with federal cannabis prohibition temper enthusiasm.

Positives

• The transaction provides a significant capital infusion of $110 million, addressing ongoing operational and financial challenges for the Company.
• The sale is part of a strategic review aimed at optimizing the Company's asset portfolio and improving its financial health.
• A substantial portion of the consideration, $80 million, is payable in cash at closing.
• The Company expects to use net proceeds to redeem existing Senior Secured Notes, which could strengthen its balance sheet.
• A 15-business-day 'go-shop' period allows the Company to solicit and negotiate alternative proposals, potentially leading to a better offer.

Negatives

• The $20 million Delayed Payment is contingent on the achievement of adult-use sales at all six Virginia retail locations or 12 months from the first adult-use sale, with the obligation terminating if conditions are not met within seven years of the Closing Date.
• The $10 million promissory note is subject to downward adjustments for cash, working capital, indebtedness, transaction expenses of gLeaf Virginia, and indemnification claims.
• A $3.3 million break-up fee is payable by Cannabist if it enters into an alternative proposal or fails to obtain the required Noteholder Consent.
• Cannabist is required to pay up to $350,000 of the Buyer's actually incurred transaction expenses, which is non-refundable.

Risks

• The transaction requires regulatory approvals from the Virginia Cannabis Control Authority and other applicable Governmental Entities, which may not be obtained or could be subject to conditions.
• Consent and lien releases from the requisite holders of the Company's 9.25% Senior Secured Notes and 9.0% Senior Secured Convertible Notes are critical closing conditions.
• The U.S. federal government classifies marijuana as a Schedule I controlled substance under the Controlled Substances Act (CSA), making cultivation, production, distribution, and sale illegal under federal law, exposing parties to civil forfeiture and criminal penalties despite state-level legality. This is an 'Excluded Federal Claim' risk.
• There is continuing uncertainty regarding if and when U.S. federal regulatory changes, such as those related to Section 280E of the Internal Revenue Code, may occur, impacting the Company and the industry.
• The Company faces a risk of a Material Adverse Effect occurring prior to closing, which could impact the transaction.
• The conditions for the $20 million Delayed Payment may not be met within the seven-year timeframe, leading to the termination of that payment obligation.

Future Outlook

The Company expects to use a portion of the net proceeds from the transaction to redeem its Senior Secured Notes. The sale is a key component of a broader strategic review aimed at addressing ongoing operational and financial challenges within the Company and the cannabis industry, as well as navigating the continuing uncertainty surrounding U.S. federal regulatory changes, particularly regarding taxation under Section 280E of the Internal Revenue Code.

Management Comments

• "The Board of Directors of the Company formed a special committee of independent directors (the Special Committee) to review strategic alternatives."
• "The Special Committee, with support from external financial and legal advisors, is considering a range of options, including potential asset sales, mergers, or other strategic or financial transactions."
• "The review is being conducted in consideration of the ongoing operational and financial challenges for the Company and the industry, as well as of the continuing uncertainty as to if and when U.S. federal regulatory changes may occur that will impact the Company and the industry, including, without limitation, changes to U.S. federal taxation of the Company and the industry under Section 280(e) of the Internal Revenue Code."
• "The Transaction forms part of this strategic review."

Industry Context

The U.S. cannabis industry continues to face significant operational and financial challenges, compounded by the persistent conflict between state-legal cannabis operations and federal prohibition under the Controlled Substances Act. This legal dichotomy creates unique risks, including potential civil forfeiture and criminal penalties, and complicates financial and tax planning due to Section 280E of the Internal Revenue Code. The Cannabist Company's strategic divestiture of its Virginia assets to Curaleaf reflects a broader industry trend of companies seeking to optimize their portfolios, reduce debt, and streamline operations in a complex and evolving regulatory landscape.

Corporate Governance

Legal Proceedings

• The filing explicitly highlights that while certain states authorize cannabis activities, the U.S. Federal Controlled Substances Act (CSA) classifies marijuana as a Schedule I controlled substance, making its manufacture, distribution, or possession illegal under federal law.
• This federal prohibition exposes any individual or entity participating in a state-legal marijuana business to potential civil forfeiture of assets or criminal penalties.
• The representations and warranties regarding compliance with laws are specifically qualified by the fundamental nature of the Parties' business, which is not in compliance with Federal Cannabis Laws.
• No proceeding may be brought by any party arising in connection with an 'Excluded Federal Claim' (claims related to federal marijuana laws).

Stakeholder Impact

• Shareholders: Potential for improved financial health through debt reduction and strategic focus, but also potential for dilution if the strategic review leads to other capital actions. The 'go-shop' period offers a chance for potentially higher offers.
• Noteholders: Consent is required for the transaction, and a portion of proceeds is expected to redeem Notes, potentially benefiting them through early repayment.
• Employees: Employees of gLeaf Virginia will either be offered employment by the Buyer (Transferred Employees) or terminated by Cannabist (Non-Transferred Employees), with Cannabist responsible for all pre-closing obligations and severance for Non-Transferred Employees.
• Customers: The change in ownership of Virginia operations may impact customers, though the filing does not detail specific changes to operations or brands.

Next Steps

• Obtain all necessary regulatory approvals, including from the Virginia Cannabis Control Authority.
• Secure consent and lien releases from the holders of the Company's Senior Secured Notes.
• Negotiate, finalize, and enter into an escrow agreement with an escrow agent for the $3.3 million Escrow Amount.
• Close the transaction, which is expected to occur early in 2026 or before.
• The Company will continue its 'go-shop' period until December 22, 2025, to solicit alternative proposals.
• The Company plans to use a portion of the net proceeds from the transaction to redeem its Senior Secured Notes.

Key Dates

Keywords

Cannabis, Curaleaf, Cannabist Company, Asset Sale, Virginia, SEC Filing, M&A, Equity Purchase Agreement, Promissory Note, Strategic Review, Marijuana, 280E, Regulatory Approval